Feraheme (ferumoxytol injection) / Azurity Pharma - LARVOL DELTA

Optimizing Adherence to Intravenous Iron: A Geographic Analysis of Variability Within the United States (ISPOR 2025) - "Single-dose ferric derisomaltose had higher adherence than two-dose ferumoxytol and ferric carboxymaltose. This analysis highlights the variability in IVI adherence across healthcare plans and regions, with south and west regions showing the highest and lowest adherence, respectively. This analysis highlights the variability in IVI adherence across healthcare plans and regions, with south and west regions showing the highest and lowest adherence, respectively. Ferric derisomaltose showed the highest adherence, suggesting potential to simplify regimens and optimize therapy. These findings emphasize the need to better understand how regional care systems and product-specific factors, individually or combined, can optimize outcomes in IDA through adherence."

Adherence • Anemia • Hematological Disorders

Reporting Rates and Medical Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Different Intravenous Iron Products Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) (ISPOR 2025) - "OBJECTIVES: To evaluate adverse events (AEs) associated with different intravenous (IV) iron products and related medical costs in the United States using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Primary suspect cases associated with ferric carboxymaltose (FCM), ferumoxytol (FM), ferric derisomaltose (FD), sodium ferric gluconate complex in sucrose (FG), iron dextran and iron sucrose (IS) were evaluated (1 January, 2014 to 30 June, 2024), including anaphylactic reaction and hypersensitivity. FCM showed the lowest reporting rates of anaphylaxis and hypersensitivity related AEs and also the lowest downstream medical costs per anaphylactic reaction, compared to the other IV iron products. FCM may decrease the economic burden on patients and healthcare plans by reducing anaphylaxis and hypersensitivity related AEs and associated medical costs per anaphylactic reaction."

Adverse events • HEOR • Immunology

Ferumoxytol promotes haematopoietic stem cell post-injury regeneration as a reactive oxygen species scavenger. (PubMed, Nat Nanotechnol) - "Moreover, FMT maintains long-term regenerative capacity of transplanted HSCs in pre-conditioned leukaemic mice and shows potential to effectively eliminate leukaemia in vivo while preserving HSCs. Our study highlights FMT as a powerful clinical tool to promote haematopoietic cell recovery in patients undergoing stress-generating treatments."

Journal • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Transplantation • CAT

Nanoparticles may influence mast cells gene expression profiles without affecting their degranulation function. (PubMed, Nanomedicine) - "The assayed nanoparticles included four clinical-grade nanomedicines (Abraxane, Doxil, AmBisome, and Feraheme) and three commercial research-grade nanomaterials (generation 5 PAMAM dendrimers with carboxy-, hydroxy-, or amine- surface functionalities). Interestingly, Feraheme induced DEG without affecting degranulation. These data demonstrate that some nanomaterials have more effects on immune cells than can be detected by a functional immunoassay."

Journal • Allergy • Immunology • Oncology

MORPHOLOGICAL DETERMINANTS OF INTRACARDIAC FLOW ENERGETICS IN SINGLE VENTRICLE PATIENTS:AFONTAN AND PRE-FONTAN ANALYSIS USING 4D FLOW MRI - Ryan P. O'Hara (ACC 2025) - "This study aimed to identify morphological determinants of kinetic energy (KE) and energy loss (EL) in SV patients using 4D flow analysis. A retrospective analysis of pre-Fontan and Fontan patients who underwent ferumoxytol- or gadolinium-enhanced CMR was performed... 4D flow analysis reveals significant differences in SV hemodynamics. In the Fontan cohort, the Ventricular Morphology appeared to have the biggest impact on the flow dynamics. Ventricular morphology significantly impacts flow in Fontan patients, warranting further study into long-term outcomes."

Clinical • Cardiovascular • Heart Failure

Characterizing Extravascular Lung Water - A Dual Contrast Agent Extracellular Volume Approach by Cardiovascular Magnetic Resonance. (PubMed, J Cardiovasc Magn Reson) - "Extravascular lung ECV measurements and derived lung water volumes corresponded well with predicted increases in extravascular and intravascular pulmonary fluid in animal models. This method may enable mechanistic studies of lung water in patients with dyspnea."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Disease • Respiratory Diseases

Improved Outcomes with Intravenous Compared to Oral Iron for Iron Deficiency Anemia in Pregnancy (IARS-SOCCA 2025) - "We identified pregnant patients aged ≥18 years with iron deficiency anemia (IDA) (ICD10-CM D50) or anemia impacting pregnancy, constructing two cohorts: (1) 10,834 patients treated with IV iron, i.e. iron sucrose (RxNorm 24909), iron dextran (5992), sodium ferric gluconate (261435), ferric carboxymaltose (1433693), or ferumoxytol (473387), and (2) 64,588 patients treated with oral iron including ferrous sulfate (24942), ferrous fumarate (24941), or ferrous gluconate (24947) within 2 months of the 2nd trimester (Z3A.2) (Figure 1).We propensity score matched by age, race, gender, ethnicity, sex, overweight and obesity (ICD10-CM E66), type 2 diabetes (E11), lipid disorders (E78), essential hypertension (I10), heart failure (I50), chronic ischemic heart disease (I25), hypothyroidism (E03), chronic kidney disease (N18), neoplasms (C00-D49), nicotine dependence (F17), alcohol use disorder (F10.10), and pre-treatment Hb split into: life-threatening (<6.5 g/dL), severe (6.5-8..."

Addiction (Opioid and Alcohol) • Anemia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Constipation • Coronary Artery Disease • Diabetes • Dyslipidemia • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Nicotine Addiction • Obesity • Oncology • Renal Disease • Type 2 Diabetes Mellitus

Conventional and complementary alternative medicine therapies for renal anemia: a literature review. (PubMed, Front Endocrinol (Lausanne)) - "The article details the effects of Roxadustat, Ferumoxytol, and Epodion. Clinical trials suggest that CAM therapy can improve renal anemia through mechanisms such as enhanced iron metabolism, anti-inflammatory effects, reduced hepcidin levels, and increased EPO and HIF expressions. By synthesizing this information, the review aims to furnish valuable insights and treatment recommendations aimed at ameliorating renal anemia in individuals grappling with chronic kidney disease."

Journal • Review • Anemia • Chronic Kidney Disease • Fatigue • Hematological Disorders • Inflammation • Nephrology • Renal Disease

Intravenous Iron Reactions: Lessons For The Allergist (AAAAI-WAO 2025) - "Reactions occurred to iron sucrose (55%), iron dextran (19%), ferric carboxymaltose (11%), ferric derisomaltose (3%), ferric gluconate (3%), ferumoxytol (3%), on initial (63%) or subsequent (31%) infusions both immediate (6-hours, 10%). Management (63%) involved emergency presentation (27%) and included antihistamines (48%), steroids (29%), epinephrine (13%), intravenous fluids (10%), phosphorous (3%)...We suggest most patients tolerate future FEIV with antihistamine pre-treatment and slower infusion rates supporting a non-IgE mechanism. We also highlight hypophosphatemia as an underrecognized adverse drug reaction related to specific FEIV."

Immunology • Renal Disease

Development of an interactive ultra-high resolution magnetic resonance neurography atlas of the brachial plexus and upper extremity peripheral nerves. (PubMed, Clin Imaging) - "A detailed and interactive MR neurography atlas of the brachial plexus and upper extremity was successfully developed to depict small nerves and fascicular detail with unprecedented spatial and contrast resolution. This freely available online resource (https://www.hss.edu/MRNatlas) can be used as an educational tool and clinical reference. The techniques utilized in this project serve as a framework for continued work in expanding the atlas to cover other peripheral nerve territories."

Biomarker • Clinical • Clinical guideline • Journal • Observational data • Retrospective data • Review • Pain

XACT-Fe-GBM-01: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Bryan Allen | Recruiting ➔ Active, not recruiting | N=12 ➔ 17

Enrollment change • Enrollment closed • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Decoration of Autophagy Detecting Nanoparticle with an Anionic Fluorochrome Enhances Multispectral Characterization of Autophagosome Location and Flux. (PubMed, Small) - "ADN2 co-localized strongly with LC3-GFP positive autophagosomes and provided readouts of in vivo probe delivery and activation in the hearts of fed/starved mice. ADN2 enhances the ability to image autophagy without genetic transfection of cells/animals and underscores the possible effects for unanticipated interactions between fluorochromes and other moieties on the surface of decorated nanoparticles."

Journal • Gene Therapies • ATG7 • CTSC

Evaluation of aortic stent endoleaks in the renally impaired patient with ferumoxytol-enhanced MR angiography. (PubMed, Clin Imaging) - "For patients with a history of AAA and CKD status post EVAR, FE-MRA is a safe, practical and effective imaging solution for evaluation of Type I and Type II endoleaks."

Journal • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

XACT-Fe-GBM-01: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Bryan Allen | Active, not recruiting ➔ Recruiting

Enrollment open • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy. (PubMed, Cochrane Database Syst Rev) - "Intravenous iron likely slightly increases Hb levels and likely reduces anaemia in pregnancy compared to oral iron. Hb levels postpartum may be slightly increased with intravenous iron, but the effect on postpartum severe anaemia status is very uncertain. Intravenous iron may result in little to no difference in PPH, and blood transfusion rates are likely unaffected by route of administration. Synthesis of adverse outcomes proved challenging due to their rarity and suboptimal reporting. The effects of intravenous iron on maternal mortality and admissions to the ICU are very uncertain, and there is likely little to no difference between groups in severe infections and prolonged hospital stay. Intravenous iron likely does not increase AEs and may not increase serious AEs; however, the 95% CIs in both cases include potential harm. Furthermore, this finding should be treated cautiously due to the varied adverse event profiles of both types of iron preparations. Data from the..."

Clinical • Journal • Review • Anemia • Critical care • Hematological Disorders • Infectious Disease • Postpartum Hemorrhage

DIVI: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Washington | Trial completion date: Jun 2027 ➔ Dec 2027 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders

Evaluation of High Dose Ferumoxytol Feraheme for Peripheral Lymphangiogram at a Pediatric Institution (ASHP 2024) - No abstract available

Clinical • Pediatrics

Stand vs Alternative Ferumoxytol Dosing A retrospective view on Iron Stores PostReplacement Therapy (ASHP 2024) - No abstract available

Retrospective data

Ferumoxytol nanozymes effectively target chronic biofilm infections in apical periodontitis. (PubMed, J Clin Invest) - "Notably, FMX activates SCAP pluripotency and WNT/NOTCH signaling that induces its osteogenic capacity. Together, we show FMX nanozymes are clinically effective against severe chronic biofilm infection with pathogen targeting and unique stem cell-stimulatory properties, offering a regenerative approach to antimicrobial therapy."

Journal • Dental Disorders • Infectious Disease • Periodontitis

XACT-Fe-GBM-01: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Bryan Allen | Suspended ➔ Active, not recruiting

Enrollment closed • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia (clinicaltrials.gov) - P3 | N=80 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Anemia • Hematological Disorders

Is All Iron Created Equal: A Retrospective Cohort Analysis of Postoperative Outcomes Associated with Intravenous Iron Formulations (ASA 2024) - "We included iron sucrose (RxNorm 24909), iron dextran (5992), sodium ferric gluconate (261435), ferric carboxymaltose (1433693), and ferumoxytol (473387) for analysis. Iron therapy is an important tool for treating IDA in the preoperative period and our findings show that inexpensive intravenous iron preparations may result in the same or better outcomes than more expensive ones. Choosing the ideal iron preparation for preoperative IDA treatment may lead to higher value care."

Retrospective data • Anemia • Anesthesia • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Heart Failure • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Obesity • Oncology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Relaxivity and In Vivo Human Performance of Brand Name Versus Generic Ferumoxytol. (PubMed, Invest Radiol) - "Brand name and generic ferumoxytol products can be used interchangeably for MRA."

Journal • Preclinical

Enhancement of the lymphatic system following intravenous administration of ferumoxytol. (PubMed, Pediatr Radiol) - "The enhancement of the thoracic lymphatic duct on T1-weighted imaging, coupled with degradation observed on T2-weighted imaging, suggests that intravenously administered ferumoxytol rapidly enters the lymphatic fluid. To prevent T2 shortening from degrading the imaging results, T2-weighted imaging for lymphatic evaluation should be performed prior to the administration of ferumoxytol. Sedation and, by inference, fasting may influence this property and warrant further investigation in future studies."

Journal • Anesthesia • Cardiovascular • Heart Failure

Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. (PubMed, J Clin Sleep Med) - "The following recommendations are intended as a guide for clinicians in choosing a specific treatment for RLS and PLMD in adults and children. Each recommendation statement is assigned a strength ("Strong" or "Conditional"). A "Strong" recommendation (i.e., "We recommend…") is one that clinicians should follow under most circumstances. The recommendations listed below are ranked in the order of strength of recommendations and grouped by class of treatments within each PICO question. Some recommendations include remarks that provide additional context to guide clinicians with implementation of this recommendation."

Clinical guideline • Journal • Chronic Kidney Disease • Movement Disorders • Nephrology • Obstructive Sleep Apnea • Pediatrics • Renal Disease • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder